Skip to main content

Leukodystrophy, Hypomyelinating, 15

OMIM ID:

autosomal recessive

Leukodystrophy, Hypomyelinating, 15

Alternate Names

HLD15

Defective Genes

EPRS

Clinical Characteristics

Ocular Features

Severe optic atrophy with marked vision loss is commonly present.  Hypermetropia and nystagmus have also been reported.

Systemic Features

The clinical features of 4 unrelated patients are highly variable.  Onset of clinical signs is also variable and most are progressive.   Several patients have presented in the first month of life with microcephaly and delayed motor development.  Progressive cerebellar signs of ataxia with dystonia, dysphagia and motor signs from infancy has been seen.  Other patients with cognitive deterioration and progressive neurologic deficits may present late in the first decade of life at which time ataxia, dysarthria, spasticity, and pyramidal signs nay also be noted.  Dystonic and athetoid movements and intention tremor have been reported in some patients.

Brain MRIs in older individuals in the second decade of life reveal hypomyelinating leukodystrophy with thinning of the corpus callosum and cerebellar atrophy.

Genetics

Inheritance

Homozygous or compound heterozygous mutations in the EPRS (1q41) gene are responsible for this autosomal recessive disorder.

Pedigree

Autosomal recessive

In order for autosomal recessive disorders to be expressed, offspring generally must inherit two mutations, one from each carrier parent.  Carriers with only one mutation, such as the parents, do not have clinical disease.  Note that carrier parents can expect that 1 in 4 children (25%) will inherit both mutations and have the disorder, 2 in 4 children (50%) will be carriers like their parents, while 1 in 4 children (25%) inherit neither mutation.

Image
Sample pedigree of autosomal recessive inheritance

In order for autosomal recessive disorders to be expressed, offspring generally must inherit two mutations, one from each carrier parent. Carriers with only one mutation, such as the parents, do not have clinical disease. Note that carrier parents can expect that 1 in 4 children (25%) will inherit both mutations and have the disorder, 2 in 4 children (50%) will be carriers like their parents, while 1 in 4 children (25%) inherit neither mutation.

Treatment & Management

No treatment has been reported.

Publications